世界の二重特異性抗体療法市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Bi-Specific Antibodies Therapy Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0857
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、93ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、二重特異性抗体療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（非対称抗体、対称抗体、フラグメント抗体）、用途別市場規模（結腸がん、前立腺がん、子宮頸がん、乳がん、肺がん、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・二重特異性抗体療法の市場動向
・企業の競争状況、市場シェア
・二重特異性抗体療法の種類別市場規模（非対称抗体、対称抗体、フラグメント抗体）
・二重特異性抗体療法の用途別市場規模（結腸がん、前立腺がん、子宮頸がん、乳がん、肺がん、その他）
・二重特異性抗体療法の北米市場規模2016-2027（アメリカ、カナダ）
・二重特異性抗体療法のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・二重特異性抗体療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・二重特異性抗体療法の中南米市場規模2016-2027（メキシコ、ブラジル）
・二重特異性抗体療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Amgen Inc.、Roche、AbbVie Inc.、OncoMed Pharmaceuticals, Inc.、Glenmark Pharmaceuticals Limited、Xencor, Inc.、MacroGenics, Inc.、Aptevo Therapeutics Inc.、Ligand Pharmaceuticals, Inc.、Regeneron Pharmaceuticals, Inc.、Fresenius、Merus）
・結論

The Bi-Specific Antibody is a synthetic protein that comes across as a combination of wreckages of two dissimilar monoclonal antibodies and binds two dissimilar categories of antigen.
Cancer immunotherapy is the most extensively discovered use of bispecific antibody. Colon, Brest, and Lung cancer are the widespread uses of Bi-Specific Antibody. Bi-Specific Antibody, at the same time, gets fixed to a cytotoxic cell, marks cancer cell, and terminates it.

Market Analysis and Insights: Global Bi-Specific Antibodies Therapy Market
The global Bi-Specific Antibodies Therapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bi-Specific Antibodies Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bi-Specific Antibodies Therapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bi-Specific Antibodies Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bi-Specific Antibodies Therapy market.

Global Bi-Specific Antibodies Therapy Scope and Market Size
Bi-Specific Antibodies Therapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Bi-Specific Antibodies Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Asymmetric Antibodies
Symmetric Antibodies
Fragment Antibodies

Segment by Application
Colon Cancer
Prostate Cancer
Cervical Cancer
Breast Cancer
Lung Cancer
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Amgen Inc.
Roche
AbbVie Inc.
OncoMed Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Limited
Xencor, Inc.
MacroGenics, Inc.
Aptevo Therapeutics Inc.
Ligand Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Asymmetric Antibodies
1.2.3 Symmetric Antibodies
1.2.4 Fragment Antibodies
1.3 Market by Application
1.3.1 Global Bi-Specific Antibodies Therapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Colon Cancer
1.3.3 Prostate Cancer
1.3.4 Cervical Cancer
1.3.5 Breast Cancer
1.3.6 Lung Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Bi-Specific Antibodies Therapy Market Perspective (2016-2027)
2.2 Bi-Specific Antibodies Therapy Growth Trends by Regions
2.2.1 Bi-Specific Antibodies Therapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Bi-Specific Antibodies Therapy Historic Market Share by Regions (2016-2021)
2.2.3 Bi-Specific Antibodies Therapy Forecasted Market Size by Regions (2022-2027)
2.3 Bi-Specific Antibodies Therapy Industry Dynamic
2.3.1 Bi-Specific Antibodies Therapy Market Trends
2.3.2 Bi-Specific Antibodies Therapy Market Drivers
2.3.3 Bi-Specific Antibodies Therapy Market Challenges
2.3.4 Bi-Specific Antibodies Therapy Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue
3.1.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue (2016-2021)
3.1.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Players (2016-2021)
3.2 Global Bi-Specific Antibodies Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Bi-Specific Antibodies Therapy Revenue
3.4 Global Bi-Specific Antibodies Therapy Market Concentration Ratio
3.4.1 Global Bi-Specific Antibodies Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bi-Specific Antibodies Therapy Revenue in 2020
3.5 Bi-Specific Antibodies Therapy Key Players Head office and Area Served
3.6 Key Players Bi-Specific Antibodies Therapy Product Solution and Service
3.7 Date of Enter into Bi-Specific Antibodies Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Bi-Specific Antibodies Therapy Breakdown Data by Type
4.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Type (2016-2021)
4.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2022-2027)

5 Bi-Specific Antibodies Therapy Breakdown Data by Application
5.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Application (2016-2021)
5.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Bi-Specific Antibodies Therapy Market Size (2016-2027)
6.2 North America Bi-Specific Antibodies Therapy Market Size by Type
6.2.1 North America Bi-Specific Antibodies Therapy Market Size by Type (2016-2021)
6.2.2 North America Bi-Specific Antibodies Therapy Market Size by Type (2022-2027)
6.2.3 North America Bi-Specific Antibodies Therapy Market Size by Type (2016-2027)
6.3 North America Bi-Specific Antibodies Therapy Market Size by Application
6.3.1 North America Bi-Specific Antibodies Therapy Market Size by Application (2016-2021)
6.3.2 North America Bi-Specific Antibodies Therapy Market Size by Application (2022-2027)
6.3.3 North America Bi-Specific Antibodies Therapy Market Size by Application (2016-2027)
6.4 North America Bi-Specific Antibodies Therapy Market Size by Country
6.4.1 North America Bi-Specific Antibodies Therapy Market Size by Country (2016-2021)
6.4.2 North America Bi-Specific Antibodies Therapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Bi-Specific Antibodies Therapy Market Size (2016-2027)
7.2 Europe Bi-Specific Antibodies Therapy Market Size by Type
7.2.1 Europe Bi-Specific Antibodies Therapy Market Size by Type (2016-2021)
7.2.2 Europe Bi-Specific Antibodies Therapy Market Size by Type (2022-2027)
7.2.3 Europe Bi-Specific Antibodies Therapy Market Size by Type (2016-2027)
7.3 Europe Bi-Specific Antibodies Therapy Market Size by Application
7.3.1 Europe Bi-Specific Antibodies Therapy Market Size by Application (2016-2021)
7.3.2 Europe Bi-Specific Antibodies Therapy Market Size by Application (2022-2027)
7.3.3 Europe Bi-Specific Antibodies Therapy Market Size by Application (2016-2027)
7.4 Europe Bi-Specific Antibodies Therapy Market Size by Country
7.4.1 Europe Bi-Specific Antibodies Therapy Market Size by Country (2016-2021)
7.4.2 Europe Bi-Specific Antibodies Therapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size (2016-2027)
8.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Type
8.2.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Application
8.3.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region
8.4.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Bi-Specific Antibodies Therapy Market Size (2016-2027)
9.2 Latin America Bi-Specific Antibodies Therapy Market Size by Type
9.2.1 Latin America Bi-Specific Antibodies Therapy Market Size by Type (2016-2021)
9.2.2 Latin America Bi-Specific Antibodies Therapy Market Size by Type (2022-2027)
9.2.3 Latin America Bi-Specific Antibodies Therapy Market Size by Type (2016-2027)
9.3 Latin America Bi-Specific Antibodies Therapy Market Size by Application
9.3.1 Latin America Bi-Specific Antibodies Therapy Market Size by Application (2016-2021)
9.3.2 Latin America Bi-Specific Antibodies Therapy Market Size by Application (2022-2027)
9.3.3 Latin America Bi-Specific Antibodies Therapy Market Size by Application (2016-2027)
9.4 Latin America Bi-Specific Antibodies Therapy Market Size by Country
9.4.1 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2016-2021)
9.4.2 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size (2016-2027)
10.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Type
10.2.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Application
10.3.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country
10.4.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Details
11.1.2 Amgen Inc. Business Overview
11.1.3 Amgen Inc. Bi-Specific Antibodies Therapy Introduction
11.1.4 Amgen Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.1.5 Amgen Inc. Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Bi-Specific Antibodies Therapy Introduction
11.2.4 Roche Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.2.5 Roche Recent Development
11.3 AbbVie Inc.
11.3.1 AbbVie Inc. Company Details
11.3.2 AbbVie Inc. Business Overview
11.3.3 AbbVie Inc. Bi-Specific Antibodies Therapy Introduction
11.3.4 AbbVie Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.3.5 AbbVie Inc. Recent Development
11.4 OncoMed Pharmaceuticals, Inc.
11.4.1 OncoMed Pharmaceuticals, Inc. Company Details
11.4.2 OncoMed Pharmaceuticals, Inc. Business Overview
11.4.3 OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Introduction
11.4.4 OncoMed Pharmaceuticals, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.4.5 OncoMed Pharmaceuticals, Inc. Recent Development
11.5 Glenmark Pharmaceuticals Limited
11.5.1 Glenmark Pharmaceuticals Limited Company Details
11.5.2 Glenmark Pharmaceuticals Limited Business Overview
11.5.3 Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Introduction
11.5.4 Glenmark Pharmaceuticals Limited Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.5.5 Glenmark Pharmaceuticals Limited Recent Development
11.6 Xencor, Inc.
11.6.1 Xencor, Inc. Company Details
11.6.2 Xencor, Inc. Business Overview
11.6.3 Xencor, Inc. Bi-Specific Antibodies Therapy Introduction
11.6.4 Xencor, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.6.5 Xencor, Inc. Recent Development
11.7 MacroGenics, Inc.
11.7.1 MacroGenics, Inc. Company Details
11.7.2 MacroGenics, Inc. Business Overview
11.7.3 MacroGenics, Inc. Bi-Specific Antibodies Therapy Introduction
11.7.4 MacroGenics, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.7.5 MacroGenics, Inc. Recent Development
11.8 Aptevo Therapeutics Inc.
11.8.1 Aptevo Therapeutics Inc. Company Details
11.8.2 Aptevo Therapeutics Inc. Business Overview
11.8.3 Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Introduction
11.8.4 Aptevo Therapeutics Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.8.5 Aptevo Therapeutics Inc. Recent Development
11.9 Ligand Pharmaceuticals, Inc.
11.9.1 Ligand Pharmaceuticals, Inc. Company Details
11.9.2 Ligand Pharmaceuticals, Inc. Business Overview
11.9.3 Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Introduction
11.9.4 Ligand Pharmaceuticals, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.9.5 Ligand Pharmaceuticals, Inc. Recent Development
11.10 Regeneron Pharmaceuticals, Inc.
11.10.1 Regeneron Pharmaceuticals, Inc. Company Details
11.10.2 Regeneron Pharmaceuticals, Inc. Business Overview
11.10.3 Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Introduction
11.10.4 Regeneron Pharmaceuticals, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.10.5 Regeneron Pharmaceuticals, Inc. Recent Development
11.11 Fresenius
11.11.1 Fresenius Company Details
11.11.2 Fresenius Business Overview
11.11.3 Fresenius Bi-Specific Antibodies Therapy Introduction
11.11.4 Fresenius Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.11.5 Fresenius Recent Development
11.12 Merus
11.12.1 Merus Company Details
11.12.2 Merus Business Overview
11.12.3 Merus Bi-Specific Antibodies Therapy Introduction
11.12.4 Merus Revenue in Bi-Specific Antibodies Therapy Business (2016-2021)
11.12.5 Merus Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Asymmetric Antibodies
Table 3. Key Players of Symmetric Antibodies
Table 4. Key Players of Fragment Antibodies
Table 5. Global Bi-Specific Antibodies Therapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Bi-Specific Antibodies Therapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Bi-Specific Antibodies Therapy Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Bi-Specific Antibodies Therapy Market Share by Regions (2016-2021)
Table 9. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Bi-Specific Antibodies Therapy Market Share by Regions (2022-2027)
Table 11. Bi-Specific Antibodies Therapy Market Trends
Table 12. Bi-Specific Antibodies Therapy Market Drivers
Table 13. Bi-Specific Antibodies Therapy Market Challenges
Table 14. Bi-Specific Antibodies Therapy Market Restraints
Table 15. Global Bi-Specific Antibodies Therapy Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Bi-Specific Antibodies Therapy Market Share by Players (2016-2021)
Table 17. Global Top Bi-Specific Antibodies Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bi-Specific Antibodies Therapy as of 2020)
Table 18. Ranking of Global Top Bi-Specific Antibodies Therapy Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Bi-Specific Antibodies Therapy Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Bi-Specific Antibodies Therapy Product Solution and Service
Table 22. Date of Enter into Bi-Specific Antibodies Therapy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Bi-Specific Antibodies Therapy Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2016-2021)
Table 26. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Bi-Specific Antibodies Therapy Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2016-2021)
Table 30. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Bi-Specific Antibodies Therapy Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Bi-Specific Antibodies Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Bi-Specific Antibodies Therapy Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Bi-Specific Antibodies Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Bi-Specific Antibodies Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Bi-Specific Antibodies Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Bi-Specific Antibodies Therapy Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Bi-Specific Antibodies Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Bi-Specific Antibodies Therapy Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Bi-Specific Antibodies Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Bi-Specific Antibodies Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Bi-Specific Antibodies Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Bi-Specific Antibodies Therapy Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Bi-Specific Antibodies Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Bi-Specific Antibodies Therapy Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Bi-Specific Antibodies Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Bi-Specific Antibodies Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Bi-Specific Antibodies Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 62. Amgen Inc. Company Details
Table 63. Amgen Inc. Business Overview
Table 64. Amgen Inc. Bi-Specific Antibodies Therapy Product
Table 65. Amgen Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 66. Amgen Inc. Recent Development
Table 67. Roche Company Details
Table 68. Roche Business Overview
Table 69. Roche Bi-Specific Antibodies Therapy Product
Table 70. Roche Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 71. Roche Recent Development
Table 72. AbbVie Inc. Company Details
Table 73. AbbVie Inc. Business Overview
Table 74. AbbVie Inc. Bi-Specific Antibodies Therapy Product
Table 75. AbbVie Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 76. AbbVie Inc. Recent Development
Table 77. OncoMed Pharmaceuticals, Inc. Company Details
Table 78. OncoMed Pharmaceuticals, Inc. Business Overview
Table 79. OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Product
Table 80. OncoMed Pharmaceuticals, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 81. OncoMed Pharmaceuticals, Inc. Recent Development
Table 82. Glenmark Pharmaceuticals Limited Company Details
Table 83. Glenmark Pharmaceuticals Limited Business Overview
Table 84. Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Product
Table 85. Glenmark Pharmaceuticals Limited Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 86. Glenmark Pharmaceuticals Limited Recent Development
Table 87. Xencor, Inc. Company Details
Table 88. Xencor, Inc. Business Overview
Table 89. Xencor, Inc. Bi-Specific Antibodies Therapy Product
Table 90. Xencor, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 91. Xencor, Inc. Recent Development
Table 92. MacroGenics, Inc. Company Details
Table 93. MacroGenics, Inc. Business Overview
Table 94. MacroGenics, Inc. Bi-Specific Antibodies Therapy Product
Table 95. MacroGenics, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 96. MacroGenics, Inc. Recent Development
Table 97. Aptevo Therapeutics Inc. Company Details
Table 98. Aptevo Therapeutics Inc. Business Overview
Table 99. Aptevo Therapeutics Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 100. Aptevo Therapeutics Inc. Recent Development
Table 101. Ligand Pharmaceuticals, Inc. Company Details
Table 102. Ligand Pharmaceuticals, Inc. Business Overview
Table 103. Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Product
Table 104. Ligand Pharmaceuticals, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 105. Ligand Pharmaceuticals, Inc. Recent Development
Table 106. Regeneron Pharmaceuticals, Inc. Company Details
Table 107. Regeneron Pharmaceuticals, Inc. Business Overview
Table 108. Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Product
Table 109. Regeneron Pharmaceuticals, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 110. Regeneron Pharmaceuticals, Inc. Recent Development
Table 111. Fresenius Company Details
Table 112. Fresenius Business Overview
Table 113. Fresenius Bi-Specific Antibodies Therapy Product
Table 114. Fresenius Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 115. Fresenius Recent Development
Table 116. Merus Company Details
Table 117. Merus Business Overview
Table 118. Merus Bi-Specific Antibodies Therapy Product
Table 119. Merus Revenue in Bi-Specific Antibodies Therapy Business (2016-2021) & (US$ Million)
Table 120. Merus Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Bi-Specific Antibodies Therapy Market Share by Type: 2020 VS 2027
Figure 2. Asymmetric Antibodies Features
Figure 3. Symmetric Antibodies Features
Figure 4. Fragment Antibodies Features
Figure 5. Global Bi-Specific Antibodies Therapy Market Share by Application: 2020 VS 2027
Figure 6. Colon Cancer Case Studies
Figure 7. Prostate Cancer Case Studies
Figure 8. Cervical Cancer Case Studies
Figure 9. Breast Cancer Case Studies
Figure 10. Lung Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. Bi-Specific Antibodies Therapy Report Years Considered
Figure 13. Global Bi-Specific Antibodies Therapy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Bi-Specific Antibodies Therapy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Bi-Specific Antibodies Therapy Market Share by Regions: 2020 VS 2027
Figure 16. Global Bi-Specific Antibodies Therapy Market Share by Regions (2022-2027)
Figure 17. Global Bi-Specific Antibodies Therapy Market Share by Players in 2020
Figure 18. Global Top Bi-Specific Antibodies Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bi-Specific Antibodies Therapy as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Bi-Specific Antibodies Therapy Revenue in 2020
Figure 20. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2016-2021)
Figure 21. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2022-2027)
Figure 22. North America Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Bi-Specific Antibodies Therapy Market Share by Type (2016-2027)
Figure 24. North America Bi-Specific Antibodies Therapy Market Share by Application (2016-2027)
Figure 25. North America Bi-Specific Antibodies Therapy Market Share by Country (2016-2027)
Figure 26. United States Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Bi-Specific Antibodies Therapy Market Share by Type (2016-2027)
Figure 30. Europe Bi-Specific Antibodies Therapy Market Share by Application (2016-2027)
Figure 31. Europe Bi-Specific Antibodies Therapy Market Share by Country (2016-2027)
Figure 32. Germany Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Region (2016-2027)
Figure 42. China Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Bi-Specific Antibodies Therapy Market Share by Type (2016-2027)
Figure 50. Latin America Bi-Specific Antibodies Therapy Market Share by Application (2016-2027)
Figure 51. Latin America Bi-Specific Antibodies Therapy Market Share by Country (2016-2027)
Figure 52. Mexico Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Country (2016-2027)
Figure 58. Turkey Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Bi-Specific Antibodies Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Amgen Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 62. Roche Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 63. AbbVie Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 64. OncoMed Pharmaceuticals, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 65. Glenmark Pharmaceuticals Limited Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 66. Xencor, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 67. MacroGenics, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 68. Aptevo Therapeutics Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 69. Ligand Pharmaceuticals, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 70. Regeneron Pharmaceuticals, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 71. Fresenius Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 72. Merus Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

以下、関連資料のご紹介

世界の二重特異性抗体療法市場規模・現状・予測（2021年-2027年）

Global Bi-Specific Antibodies Therapy Market Size, Status and Forecast 2021-2027
QYR2104Z0857 2021年4月 93Pages
QYResearch社発行の本調査資料では、二重特異性抗体療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（非対称抗体、対称抗体、フラグメント抗体）、用途別市場規模（結腸がん、前立腺がん、子宮頸がん、乳がん、肺がん、その他）、主要地域別市場規...

世界の部位別ドラッグデリバリー市場規模・現状・予測（2021年-2027年）

Global Site-Specific Drug Delivery Market Size, Status and Forecast 2021-2027
QYR2104Z6201 2021年4月 92Pages
QYResearch社発行の本調査資料では、部位別ドラッグデリバリーのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（リポソームドキソルビシン、リポソームアムホテリシンB、リポソームパクリタキセル、その他）、用途別市場規模（真菌感染症治療、がん・...

世界の特定病原体除去（SPF）動物市場規模・現状・予測（2021年-2027年）

Global Specific Pathogen Free (SPF) Animals Market Size, Status and Forecast 2021-2027
QYR2104Z5390 2021年4月 92Pages
QYResearch社発行の本調査資料では、特定病原体除去（SPF）動物のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（SPFチキン、SPFエビ、SPFウサギ、SPFマウス、その他）、用途別市場規模（研究機関、研究所、製薬会社）、主要地域別市場...

世界のプログラム可能特定用途向け集積回路（ASIC）市場規模・現状・予測（2021年-2027年）

Global Programmable Application Specific Integrated Circuit (ASIC) Market Size, Status and Forecast 2021-2027
QYR2104Z4815 2021年4月 93Pages
QYResearch社発行の本調査資料では、プログラム可能特定用途向け集積回路（ASIC）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（フルカスタム設計、ゲートアレイベース、その他）、用途別市場規模（家電、通信、自動車、工業、その他）、主要地...

世界のプログラム可能特定用途向け集積回路（ASIC）市場規模・現状・予測（2021年-2027年）

世界の小分子標的がん治療市場規模・現状・予測（2021年-2027年）

Global Small Molecule Targeted Cancer Therapy Market Size, Status and Forecast 2021-2027
QYR2104Z5300 2021年4月 90Pages
QYResearch社発行の本調査資料では、小分子標的がん治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（モノクローナル抗体、小分子、小分子薬物コンジュゲート）、用途別市場規模（リンパ腫、黒色腫、多発性骨髄腫、乳がん、前立腺がん、その他のが...

世界の乳がん用モノクローナル抗体市場規模・現状・予測（2021年-2027年）

Global Breast Cancer Monoclonal Antibodies Market Size, Status and Forecast 2021-2027
QYR2104Z0992 2021年4月 126Pages
QYResearch社発行の本調査資料では、乳がん用モノクローナル抗体のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ネイキッドMAb、コンジュゲートMAb）、用途別市場規模（病院、小売薬局、その他）、主要地域別市場規模（北米、アメリカ、ヨーロ...

世界のCD38モノクローナル抗体市場規模・現状・予測（2021年-2027年）

Global CD38 Monoclonal Antibodies Market Size, Status and Forecast 2021-2027
QYR2104Z1166 2021年4月 95Pages
QYResearch社発行の本調査資料では、CD38モノクローナル抗体のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ダラツムマブ、イサツキシマブ）、用途別市場規模（薬局、実験室用）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本...

世界の免疫腫瘍療法市場規模・現状・予測（2021年-2027年）

Global Immuno-oncology Therapy Market Size, Status and Forecast 2021-2027
QYR2104Z3058 2021年4月 92Pages
QYResearch社発行の本調査資料では、免疫腫瘍療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（モノクローナル抗体、免疫チェックポイント阻害剤、免疫系モジュレーター、癌ワクチン、その他）、用途別市場規模（病院、外来手術センター、その他）...

世界のHER2抗体市場規模・現状・予測（2021年-2027年）

Global HER2 Antibodies Market Size, Status and Forecast 2021-2027
QYR2104Z2800 2021年4月 93Pages
QYResearch社発行の本調査資料では、HER2抗体のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（トラスツズマブ、ラパチニブ、アド-トラスツズマブエムタンシン、ペルツズマブ、エベロリムス）、用途別市場規模（病院薬局、小売薬局、Eコマース）...

世界の二重特異性抗体療法市場規模・現状・予測（2021年-2027年） The Bi-Specific Antibody is a synthetic protein that comes across as a combination of wreckages of two dissimilar monoclonal antibodies and binds two dissimilar categories of antigen. Cancer immunotherapy is the most extensively discovered use of bispecific antibody. Colon, Brest, and Lung cancer ar…
世界の乳がん用モノクローナル抗体市場規模・現状・予測（2021年-2027年） Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protei…
世界の小分子標的がん治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Small Molecule Targeted Cancer Therapy Market The global Small Molecule Targeted Cancer Therapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis a…
世界の卵巣がん遺伝子治療市場規模・現状・予測（2021年-2027年） Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor…
世界の結腸がん市場規模・現状・予測（2021年-2027年） Colon cancer is the cancer of large intestine which form the lower part of the digestive system. The disease usually begins with a small, benign clusters of cells known as adenomatous polyps. If left untreated, these polyps may result into colon cancer. Therefore, regular screening for polyps throug…